Techcyte has announced that a validation study by the Contra Costa County Public Health Laboratory (CCPHL) has been accepted for presentation at the APHL 2026 Annual Conference. This study evaluated the AI-assisted ova and parasite (O&P) workflow developed by Techcyte, in collaboration with Pramana (now Evident), to assess its effectiveness in detecting parasites in stool specimens. The study’s findings will be showcased in a poster at the conference, with the poster becoming available on the APHL’s website after the event.
The research, titled “Validation of the Techcyte/Pramana Platform for the Detection of Parasites in Stool Specimens in a County Public Health Laboratory,” demonstrated a significant advancement in parasitology testing. It utilized Techcyte’s parasitology suite with trichrome and wet mount solutions, analyzing a total of 549 patient samples with paired trichrome and wet mount slides. The study achieved impressive results, boasting 97% accuracy, 98% sensitivity, and 97% specificity when compared to traditional microscopy methods. These results highlight the potential for AI-assisted workflows to enhance operational efficiency in handling increasing specimen volumes amid staffing shortages.
The integration of this AI technology into CCPHL’s workflow in January 2026 resulted in reduced turnaround times and improved efficiency while alleviating staff fatigue. Although AI plays a significant role in the workflow, traditional light microscopy continues to be used for the final confirmation of positive cases. The authors of the study emphasize that AI integration can help address workforce shortages while maintaining established diagnostic practices.
Tyler Rippy, Account Executive at Techcyte, expressed enthusiasm about the collaboration with CCPHL and the study’s contribution to advancing AI-assisted workflows in parasitology labs. Techcyte offers a comprehensive digital parasitology solution that supports various staining methods, including trichrome, wet mount, and modified acid-fast (MAF), within a unified workflow.
Techcyte, established in 2013, is committed to transforming pathology practices through AI-powered tools that enhance diagnostic testing efficiency and accuracy. The company aims to positively impact human, animal, and environmental health worldwide by collaborating with leading labs, diagnostic companies, and solution providers. Techcyte’s platform is currently designated for Research Use Only in the United States.